Press Releases :: Aurinia Pharmaceuticals Inc. (AUPH)

July 30, 2020 • 6:05 am EDT

Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

July 27, 2020 • 10:15 am EDT

Aurinia Closes US$200 Million Public Offering of Common Shares

July 22, 2020 • 11:05 pm EDT

Aurinia Prices US$200 Million Public Offering of Common Shares

July 22, 2020 • 4:08 pm EDT

Aurinia Announces Public Offering of Common Shares

July 21, 2020 • 5:27 pm EDT

Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis

June 22, 2020 • 6:05 am EDT

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

June 9, 2020 • 6:05 am EDT

Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

June 5, 2020 • 7:05 am EDT

Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress

June 3, 2020 • 6:05 am EDT

Aurinia Announces Results of Annual General Meeting

June 1, 2020 • 4:05 pm EDT

Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Select a page:

rss_feed News RSS

©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23